EP0264231A1 — Azetidinone derivatives
Assigned to Taisho Pharmaceutical Co Ltd · Expires 1988-04-20 · 38y expired
What this patent protects
2-Azetidinone derivatives represented by the following formula wherein X is a hydrogen atom, a halogen atom, a lower alkyl group, a lower alkoxy group, a hydroxyl group or a cyano group, ℓ is 1 or 2, R¹ is a lower alkyl group, a cycloalkyl group, a 1-naphthylmethyl group, an…
USPTO Abstract
2-Azetidinone derivatives represented by the following formula wherein X is a hydrogen atom, a halogen atom, a lower alkyl group, a lower alkoxy group, a hydroxyl group or a cyano group, ℓ is 1 or 2, R¹ is a lower alkyl group, a cycloalkyl group, a 1-naphthylmethyl group, an optionally substituted phenethyl group, an optionally substituted phenyl group, an optionally substituted benzyl group or a bis(alkoxycarbonyl)ethyl group, and R² is a lower alkyl group, a lower alkoxy group, an amino group, an adamantyl group, a lower alkoxycarbonylmethyl group or an optionally substituted phenyl group, are useful as blood platelet aggregation inhibiting agents.
Drugs covered by this patent
- Zetia (EZETIMIBE) · Merck & Co.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.